247 related articles for article (PubMed ID: 15313421)
21. Inhibition of human immunodeficiency virus type 1 replication by blocking IkappaB kinase with noraristeromycin.
Asamitsu K; Yamaguchi T; Nakata K; Hibi Y; Victoriano AF; Imai K; Onozaki K; Kitade Y; Okamoto T
J Biochem; 2008 Nov; 144(5):581-9. PubMed ID: 18713798
[TBL] [Abstract][Full Text] [Related]
22. Differential effects of phorbol-13-monoesters on human immunodeficiency virus reactivation.
Márquez N; Calzado MA; Sánchez-Duffhues G; Pérez M; Minassi A; Pagani A; Appendino G; Diaz L; Muñoz-Fernández MA; Muñoz E
Biochem Pharmacol; 2008 Mar; 75(6):1370-80. PubMed ID: 18241838
[TBL] [Abstract][Full Text] [Related]
23. Antiviral effects of mifepristone on human immunodeficiency virus type-1 (HIV-1): targeting Vpr and its cellular partner, the glucocorticoid receptor (GR).
Schafer EA; Venkatachari NJ; Ayyavoo V
Antiviral Res; 2006 Dec; 72(3):224-32. PubMed ID: 16889838
[TBL] [Abstract][Full Text] [Related]
24. [Molecular basis of HIV-1 latency - Part II: HIV-1 reactivation and therapeutic implications].
Cherrier T; Le Douce V; Redel L; Marban C; Aunis D; Rohr O; Schwartz C
Med Sci (Paris); 2010 Mar; 26(3):291-5. PubMed ID: 20346279
[TBL] [Abstract][Full Text] [Related]
25. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
26. Recent status of HIV-1 gene expression inhibitors.
Baba M
Antiviral Res; 2006 Sep; 71(2-3):301-6. PubMed ID: 16488488
[TBL] [Abstract][Full Text] [Related]
27. Human immunodeficiency virus reservoir might be actively eradicated as residual malignant cells by cytotoxic chemotherapy.
Yang QE
Med Hypotheses; 2004; 62(3):358-63. PubMed ID: 14975503
[TBL] [Abstract][Full Text] [Related]
28. Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1.
Choi BS; Lee HS; Oh YT; Hyun YL; Ro S; Kim SS; Hong KJ
AIDS; 2010 Feb; 24(4):609-11. PubMed ID: 20154582
[TBL] [Abstract][Full Text] [Related]
29. Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-SCID-Hu mice.
Goldstein H; Pettoello-Mantovani M; Bera TK; Pastan IH; Berger EA
J Infect Dis; 2000 Mar; 181(3):921-6. PubMed ID: 10720513
[TBL] [Abstract][Full Text] [Related]
30. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
[TBL] [Abstract][Full Text] [Related]
31. Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption.
Rozera G; Abbate I; D'Offizi G; Corpolongo A; Narciso P; Vlassi C; Martini F; Calcaterra S; Capobianchi MR
J Med Virol; 2007 Aug; 79(8):1047-54. PubMed ID: 17597482
[TBL] [Abstract][Full Text] [Related]
32. A 1,8-naphthyridone derivative targets the HIV-1 Tat-mediated transcription and potently inhibits the HIV-1 replication.
Massari S; Daelemans D; Barreca ML; Knezevich A; Sabatini S; Cecchetti V; Marcello A; Pannecouque C; Tabarrini O
J Med Chem; 2010 Jan; 53(2):641-8. PubMed ID: 19958026
[TBL] [Abstract][Full Text] [Related]
33. Effects of diterpenes from latex of Euphorbia lactea and Euphorbia laurifolia on human immunodeficiency virus type 1 reactivation.
Avila L; Perez M; Sanchez-Duffhues G; Hernández-Galán R; Muñoz E; Cabezas F; Quiñones W; Torres F; Echeverri F
Phytochemistry; 2010 Feb; 71(2-3):243-8. PubMed ID: 19897215
[TBL] [Abstract][Full Text] [Related]
34. Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8(+) T cells.
López M; Soriano V; Rallón N; Cascajero A; González-Lahoz J; Benito JM
Eur J Immunol; 2008 Jun; 38(6):1548-58. PubMed ID: 18421792
[TBL] [Abstract][Full Text] [Related]
35. Gene therapy for HIV-1 infection: are lethal genes a valuable tool?
Luque F; Oya R; Macías D; Saniger L
Cell Mol Biol (Noisy-le-grand); 2005 Sep; 51(1):93-101. PubMed ID: 16171568
[TBL] [Abstract][Full Text] [Related]
36. Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors.
Ylisastigui L; Coull JJ; Rucker VC; Melander C; Bosch RJ; Brodie SJ; Corey L; Sodora DL; Dervan PB; Margolis DM
J Infect Dis; 2004 Oct; 190(8):1429-37. PubMed ID: 15378435
[TBL] [Abstract][Full Text] [Related]
37. Why the fat lady hasn't sung: the limits of HAART.
Martinez LJ
Res Initiat Treat Action; 1999 Dec; 5(5):8-10. PubMed ID: 11366892
[TBL] [Abstract][Full Text] [Related]
38. Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART.
Negredo E; Puigdomènech I; Marfil S; Puig J; Pérez-Alvarez N; Ruiz L; Rey-Joly C; Clotet B; Blanco J
J Antimicrob Chemother; 2008 Feb; 61(2):400-4. PubMed ID: 18083750
[TBL] [Abstract][Full Text] [Related]
39. Eradication of HIV in infected patients: some potential approaches.
Yang QE
Med Sci Monit; 2004 Jul; 10(7):RA155-65. PubMed ID: 15232518
[TBL] [Abstract][Full Text] [Related]
40. The development of immune-modulating compounds to disrupt HIV latency.
Remoli AL; Marsili G; Battistini A; Sgarbanti M
Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
